CN Mobile Logo

Search form


GM Joins the STAR Hunt

GM Joins the STAR Hunt

BETHESDA, Md—General Motors Corp. is mailing information on the opportunity for a breast cancer risk assessment, available through the Study of Tamoxifen and Raloxifene (STAR), to 140,000 of its active and retired salaried female employees. STAR researchers have enrolled more than 8,500 of a planned accrual of 22,000 postmenopausal women age 35 and older. The trial compares Evista (raloxifene) and Nolvadex (tamoxifen) for reducing breast cancer risk.

By clicking Accept, you agree to become a member of the UBM Medica Community.